Biopharma pipeline
As well as identifying multiple targets that feature in biopharma development portfolios, our pipeline includes novel drug targets with genetic linkage and repositioning opportunities at all stages of development. All assets in our pipeline include patient stratification biomarkers and are available for partnering.
High-resolution patient stratification results:
- 520 Disease risk loci
- 250 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 57 Known active compounds
High-resolution patient stratification results:
- 717 Disease risk loci
- 299 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 263 Known active compounds
High-resolution patient stratification results:
- 158 Disease risk loci
- 88 Risk associated genes mapped to disease associated mechanisms
- 23 Druggable targets
- 59 Known active compounds
High-resolution patient stratification results:
- 35 Disease risk loci
- 20 Risk associated genes mapped to disease associated mechanisms
- 8 Druggable targets
- 120 Known active compounds
High-resolution patient stratification results:
- 73 Disease risk loci
- 30 Risk associated genes mapped to disease associated mechanisms
- 16 Druggable targets
- 19 Known active compounds
High-resolution patient stratification results:
- 267 Disease risk loci
- 113 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 732 Known active compounds
High-resolution patient stratification results:
- 707 Disease risk loci
- 341 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 2611 Known active compounds
High-resolution patient stratification results:
- 125 Disease risk loci
- 85 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 155 Known active compounds
High-resolution patient stratification results:
- 570 Disease risk loci
- >200 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 281 Known active compounds
High-resolution patient stratification results:
- 359 Disease risk loci
- 163 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- >300 Known active compounds
High-resolution patient stratification results:
- 233 Disease risk loci
- 136 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 74 Known active compounds
Last updated June 30, 2022
Indication extensions
We have identified hundreds of indication extension opportunities across all stages of development. These licensable assets have high market value and strong efficacy potential for repositioning into new disease areas using patient stratification biomarkers to match them to clinically relevant patient subgroups.
Last updated June 26, 2022
Upcoming innovation
We are running new disease studies all the time, adding two new chronic disease indications to our DiseaseBank every month. Contact us to talk about your priorities and discuss partnering opportunities in one of our current or upcoming disease studies.
Partner with us-
Alopecia
-
Vitiligo
-
Age-related macular degeneration
-
Biopolar disorder
-
Chronic fatigue syndrome / ME
- Inflammatory bowel disease
- Interstitial pulmonary fibrosis
- Asthma COPD overlap syndrome
- Uterine fibroids
- Prostate cancer
- Glaucoma
Please view our pipelines on a larger screen or device for the best experience.
